Cas No.: | 1832686-44-8 |
Chemical Name: | 3-(3-((1-benzylpiperidin-4-yl)methyl)-5-methyl-2-oxotetrahydropyrimidin-1(2H)-yl)benzimidamide bis(2,2,2-trifluoroacetate) |
Synonyms: | SRI31215 2TFA; SRI-31215 2TFA; SRI 31215 2TFA; SRI-31215 Bis-TFA salt; SRI 31215 Bis-TFA salt; SRI31215 Bis-TFA salt |
SMILES: | N=C(N)C1=CC=CC(N2CC(C)CN(CC3CCN(CC4=CC=CC=C4)CC3)C2=O)=C1.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O |
Formula: | C29H35F6N5O5 |
M.Wt: | 647.62 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | SRI 31215 (TFA), a triplex inhibitor of matriptase, hepsin and hepatocyte growth factor activator (HGFA) with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2[1]. |
Target: | IC50: 0.69 μM (matriptase), 0.65 μM (hepsin), 0.3 μM (HGFA)[1] |
References: | [1]. Owusu BY, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506. |